- Reaction score
- 217
Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia ("Androgenetic Alopecia") patients was cleared by the National Medical Products Administration ("NMPA"). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for Androgenetic Alopecia treatment in China and global.
Kintor Pharmaceutical : Pharma Receives IND Clearance by NMPA for KX-826's Pivotal Study to Treat Male Alopecia Patients
Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND...
www.marketscreener.com